Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma
NCT04903080Phase 1Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2022
- Primary completion
- Mar 2033
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of HER2-specific CAR T cells in ependymoma (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Number of Subjects with Dose-Limiting Toxicity in Phase I Arm at 42 days, Number of Subjects with Dose-Limiting Toxicity in Surgical Arm at 42 days and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
HER2-specific CAR T cells
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT04903080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903080.